SLN
Silence Therapeutics PLC
10.60$
-0.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | |
| 57.4% | 64.1% | 17.8% | 441.1% | 242.9% | 6.6% | 38.0% | 37.9% | 40.3% | 35.3% | 27.7% | – | 49.0% | |
| 42.6% | 35.9% | 82.2% | -341.1% | -142.9% | 93.4% | 62.0% | 62.1% | 59.7% | 64.7% | 72.3% | – | 51.0% | |
| 319.3% | 473.4% | 75.5% | 1,838.6% | 1,340.2% | 83.9% | 14,657.1% | 7,878.1% | 12,920.8% | 25,732.4% | 1,980.8% | – | 7,480.2% | |
| 177.1% | 196.0% | 42.3% | 884.3% | 490.4% | 22.2% | 5,411.3% | 2,290.6% | 3,644.7% | 10,982.4% | 1,667.7% | – | 3,458.5% | |
| 496.4% | 669.5% | 117.7% | 2,722.9% | 1,830.6% | 106.1% | 20,068.4% | 10,759.8% | 16,565.4% | 36,714.7% | 3,637.7% | – | 10,931.2% | |
| -453.9% | -633.6% | -35.6% | -3,064.0% | -1,973.5% | -12.7% | -20,006.4% | -10,697.8% | -16,505.7% | -36,650.0% | -3,565.4% | – | -10,880.2% | |
| 0.3% | 44.2% | 0.1% | 30.6% | 753.2% | 47.5% | 6,284.3% | – | – | – | – | – | – | |
| -381.0% | -713.0% | -13.2% | -2,916.6% | -2,640.8% | 97.6% | -20,091.6% | -12,207.1% | -13,180.5% | -34,617.6% | -3,544.3% | – | -9,758.9% | |
| -86.2% | -26.4% | 1.6% | -314.2% | -275.5% | 39.3% | 5,205.1% | 4.5% | 0.6% | -2.9% | – | – | – | |
| -294.9% | -686.6% | -14.7% | -2,602.3% | -2,365.3% | 58.3% | -20,091.6% | -12,211.6% | -13,181.1% | -34,617.6% | -3,544.3% | – | -9,759.2% | |
| -376.3% | -710.2% | -18.7% | -2,866.1% | -1,877.5% | 29.6% | -19,994.5% | -10,040.6% | -13,082.4% | -34,285.3% | -3,519.2% | – | -9,814.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.